In recent years, exceptional technological advances have enabled the identification and
interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading …

Metastatic dissemination occurs very early in the malignant progression of a cancer but the
clinical manifestation of metastases often takes years. In recent decades, 5-year survival of …

Over the past few decades, substantial evidence has convincingly revealed the existence of
cancer stem cells (CSCs) as a minor subpopulation in cancers, contributing to an aberrantly …

Tumours comprise a heterogeneous collection of cells with distinct genetic and phenotypic
properties that can differentially promote progression, metastasis and drug resistance …

The major current conventional types of metastatic breast cancer (MBC) treatments include
surgery, radiation, hormonal therapy, chemotherapy, or immunotherapy. Introducing …

Accumulating data suggest that metastatic dissemination often occurs early during tumour
formation, but the mechanisms of early metastatic spread have not yet been addressed …

Surgery is a mainstay treatment for patients with solid tumours. However, despite surgical
resection with a curative intent and numerous advances in the effectiveness of (neo) …

The development of life-threatening cancer metastases at distant organs requires
disseminated tumour cells' adaptation to, and co-evolution with, the drastically different …

Metastasis is the leading cause of cancer-related deaths; metastatic lesions develop from
disseminated cancer cells (DCCs) that can remain dormant. Metastasis-initiating cells are …

Metastases arise from residual disseminated tumour cells (DTCs). This can happen years
after primary tumour treatment because residual tumour cells can enter dormancy and …